Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
Rabu, 02 Juli 2025 | 13:21
HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025,
Uni-Bio Science Group Limited (the "Group")grandly held a new medical
aesthetics product launch event in Changsha, releasing the high-end
series GeneQueens of 肌顏態® and the medical device brand 金因敷®.
Many experts, KOLs and partners attended the event. This launch not
only showcased the Group's achievements in R&D, but also marked the
comprehensive layout in the "drug, medical device and Aesthetics" field.
Photo: Group photo at the launch
1、 High-end medical aesthetics: GeneQueens series
At the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM
(Human-Sequence Triple Protein Repair & Balance Ampoule). which
functions on skin repair and anti-aging. By activating cell
regeneration, it helps users restore their youthful and healthy skin
condition.
Photo: GeneQueens product image
GeneQueensTM sets a new standard for anti-aging and repair by
adding three core ingredients in sufficient quantities. Skbrella FN, as
a key ingredient for cell repair, can accelerate the healing of skin
wounds and promote the adhesion and migration of new cells. III Collagen
strongly fills the skin structure, significantly enhancing elasticity
and firmness. XVII Collagen can strengthen the connection between the
epidermis and dermis, and consolidate the youthful foundation of the
skin.
In addition, GeneQueens adopts a sterile and preservative-free formula,
relying on high-purity raw materials and patented technology, providing
users with an "instant enjoyment" precise and efficient experience. Its
unique formula and outstanding efficacy were highly recognized by many
experts on the spot.
2、金因敷showcased a variety of new products
Meanwhile, the Group also launched several new products of its medical device brand - 金因敷®, focusing on the professional repair field of medical aesthetics.
Photo: 金因敷 series product picture
金因敷® complies with strict clinical trials and quality
inspections to ensure its safety and effectiveness. The product adopts a
high-purity non-allergenic formula, which can moisturize and accelerate
wound repair. It also uses an exclusive cooling technology to relieve
postoperative swelling and pain, providing a professional solution for
sensitive skin and post-medical procedure care.
3、The latest research data was presented at CSD2025
It is worth mentioning that 肌顏態® also showcased the research
data of "The Efficacy Study of Fibronectin in the Repair of Skin Barrier
Damage for the post-medical procedure" jointly conducted with the
Cosmetics Testing Center of the Dermatology Hospital of Southern Medical
University in the poster area of the 30th Academic Conference of the
Chinese Medical Association (CSD2025). This is not only an endorsement
of the Group's research capabilities, but also provides experts and
scholars in the industry with an opportunity to gain a deeper
understanding of the 肌顏態® technology and products.
As an annual grand event in the field of dermatology and venereology in
China, CSD2025 brings together authoritative experts and scholars in
dermatology across the country, presenting multi-dimensional academic
achievements and exchanges of ideas. The poster area is one of the core
venues of the academic annual conference. Posters are not only an
important way for researchers to showcase their scientific research
achievements, but also a key link in promoting the dissemination of
academic ideas and the feedback of clinical practice.
Photo: The research poster of 肌顏態 at the CSD 2025
4、Academic speeches by several experts
Several clinical experts at the launch further recognized the significant clinical value of 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®'
s patented ingredient, Skbrella FN, demonstrates immense potential in
improving damaged sensitive skin barriers, reducing inflammatory
erythema, alleviating discomfort sensations such as burning, tightness
and itching, as well as enhancing post-laser repair and healing.
In the clinical observations over the past few months, many patients treated with 肌顏態®
have achieved remarkable therapeutic effects. The symptoms of
anesthetic allergy have been rapidly relieved, the inflammatory
pigmentation post-laser has significantly improved, the skin barrier has
been repaired, and the patient satisfaction rate is extremely high. 金因敷®
can effectively reduce redness, swelling and pain for post-medical
procedures, accelerate wound healing and shorten the recovery time.
Photo 1: 肌顏態 use case sharing by Professor Shi Ge, Director of
the Department of Plastic Surgery of the Sixth Affiliated Hospital of
Sun Yat-sen University; Photo 2: 肌顏態 use case sharing by Professor Ge
Lan, from The First Affiliated Hospital of Army Medical University;
Photo 3: Fibronectin clinical trial results sharing by Professor Ye Li,
Head of Cosmetics Testing Center at Dermatology Hospital of Southern
Medical University; Photo 4: Mr. Du Wei, CEO of Cosmetics News &
Cosmetics Business Online, analyzes cosmetics industry development
trends
6、The signing ceremony reflects the market potential
Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized: " We have
always adhered to the standards of biopharmaceuticals in creating skin
care products. The release of GeneQueens and 金因敷 is an important
milestone in building the "Drugs, Medical device and Aesthetics"
strategy and creating a full-cycle skin care solution, aiming to meet
consumers' increasingly refined skin health needs. "
Photo: Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, addressing the launch event.
Furthermore, Ms. Liu Yihua, President of Global Cosmetics Group,
attended the launch as an important guest. Uni-Bio Science Group and
Global Cosmetics Group have jointly established a medical research
co-creation biological platform. Utilizing gene-editing biosynthesis
technology, the platform has launched Skbrella FN – a highly bioactive
recombinant human fibronectin known as "皮優理".
The launch also witnessed a grand strategic signing ceremony. The Group
has achieved in-depth cooperation with many well-known medical
aesthetics chain institutions and well-known agents. This signing is not
only a high recognition of the quality and market potential of
GeneQueens and 金因敷®, but also a key step for the Group to
accelerate commercialization and expand channels. Through strong
alliances with leading channel partners, the Group will reach the core
consumers and ensure the rapid release of huge commercial value.
Photo: Group photo of the strategic signing ceremony
The successful holding of this launch not only marks a crucial step for
the Group in medical aesthetics and medical devices, but also
demonstrates the Group's in-depth layout and forward-looking vision in
the "Drugs, Medical device and Aesthetics" strategy. In the future, the
Group will continue to be guided by technology and oriented towards
clinical value, accelerate product innovation and technological
upgrading, constantly enrich pipeline, and meet the growing market
demands.